We are live on ! Find out more
OA

Oak Associates Portfolio holdings

AUM $1.49B
1-Year Est. Return 34.25%
This Fund
S&P 500
This Quarter Est. Return
+2.64%
1 Year Est. Return
+34.25%
3 Year Est. Return
+111.6%
5 Year Est. Return
+123.41%
10 Year Est. Return
+571.62%
AUM
$1.49B
AUM Growth
-$20.8M
Cap. Flow
-$39.5M
Cap. Flow %
-2.66%
Top 10 Hldgs %
46.58%
Holding
135
New
2
Increased
16
Reduced
37
Closed
6

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$5.09M
2
MSFT icon
Microsoft
MSFT
+$4.03M
3
V icon
Visa
V
+$2.27M
4
NVO
Novo Nordisk
NVO
+$1.24M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$981K

Top Sells

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$15.7M
2
META icon
Meta Platforms (Facebook)
META
+$6.33M
3
INTC icon
Intel
INTC
+$5.53M
4
EBAY icon
eBay
EBAY
+$4.55M
5
SNPS icon
Synopsys
SNPS
+$2.68M

Sector Composition

Rank Sector Weight
1 Technology 44.99%
2 Communication Services 15.72%
3 Healthcare 14.39%
4 Consumer Discretionary 11.2%
5 Financials 10.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MA icon
26
Mastercard
MA
$477B
$16.2M 1.09%
32,885
– –
ALC icon
27
Alcon
ALC
$33.1B
$16.1M 1.08%
160,988
-1,772
-1% -$167K
CI icon
28
Cigna
CI
$76.6B
$16.1M 1.08%
46,344
+1,393
+3% +$480K
AKAM icon
29
Akamai
AKAM
$16.8B
$14.7M 0.99%
146,049
+786
+0.5% +$76.6K
LH icon
30
Labcorp
LH
$24.3B
$14.2M 0.96%
63,702
+995
+2% +$219K
PFE icon
31
Pfizer
PFE
$140B
$13.7M 0.92%
474,038
+174,568
+58% +$5.09M
APH icon
32
Amphenol
APH
$188B
$12.1M 0.82%
186,424
+200
+0.1% +$13K
MCK icon
33
McKesson
MCK
$98.5B
$11.4M 0.77%
23,035
-962
-4% -$536K
CHKP icon
34
Check Point Software Technologies
CHKP
$13.3B
$11.4M 0.77%
59,008
– –
CTSH icon
35
Cognizant
CTSH
$21.5B
$11.1M 0.75%
143,845
-2,691
-2% -$200K
GPN icon
36
Global Payments
GPN
$22.1B
$10.4M 0.7%
101,601
-2,061
-2% -$214K
REGN icon
37
Regeneron Pharmaceuticals
REGN
$68.8B
$10.4M 0.7%
9,887
+61
+0.6% +$67.9K
QRVO icon
38
Qorvo
QRVO
$7.63B
$10.3M 0.69%
100,007
– –
MCHP icon
39
Microchip Technology
MCHP
$42.8B
$9.9M 0.67%
123,349
– –
DOX icon
40
Amdocs
DOX
$5.53B
$9.59M 0.65%
109,637
-15,000
-12% -$1.26M
ZBH icon
41
Zimmer Biomet
ZBH
$17.7B
$9.35M 0.63%
86,570
+527
+0.6% +$57.5K
LMT icon
42
Lockheed Martin
LMT
$134B
$8.77M 0.59%
15,001
– –
AIZ icon
43
Assurant
AIZ
$13.7B
$8.21M 0.55%
41,303
– –
BNY
44
Bank of New York Mellon
BNY
$108B
$7.7M 0.52%
107,177
+11
+0% +$723
GILD icon
45
Gilead Sciences
GILD
$161B
$6.97M 0.47%
83,105
+424
+0.5% +$32.4K
AIT icon
46
Applied Industrial Technologies
AIT
$12.8B
$5.61M 0.38%
25,122
-250
-1% -$51K
ISRG icon
47
Intuitive Surgical
ISRG
$121B
$5.26M 0.35%
10,710
– –
STT icon
48
State Street
STT
$50.9B
$5M 0.34%
56,504
-1,621
-3% -$134K
PAYX icon
49
Paychex
PAYX
$40.4B
$4.79M 0.32%
35,715
– –
CRM icon
50
Salesforce
CRM
$134B
$4.7M 0.32%
17,181
-264
-2% -$67.6K
1
2
3 4 5

Similar funds

FAT
First American Trust Santa Ana, California $1.49B AUM 21.98% 1-Year Est. Return
AIA
Ally Invest Advisors Charlotte, North Carolina $1.49B AUM 14.08% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.49B AUM 10.4% 1-Year Est. Return
PIM
Plato Investment Management Sydney, NSW, Australia $1.49B AUM 28.65% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RIM
Rush Island Management New York $1.49B AUM 4.65% 1-Year Est. Return
SB
Simmons Bank Pine Bluff, Arkansas $1.49B AUM 23.32% 1-Year Est. Return
MHS
M Holdings Securities Portland, Oregon $1.48B AUM 26.15% 1-Year Est. Return

Oak Associates's Q3 2024 Portfolio in Review

As of Q3 2024, Oak Associates held 135 positions worth $1.49B, down 1.4% from $1.51B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Oak Associates's Q3 2024 filing shows 2 new, 16 increased, 37 reduced and 6 closed positions. Its largest new stake was Novo Nordisk: 9,283 shares worth $1.11M. The largest sale was KLA, an estimated $15.7M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, down from 46% a quarter earlier, followed by Communication Services and Healthcare.

  • Oak Associates's largest Q3 2024 buy was Novo Nordisk: 9,283 shares worth $1.11M.
  • Oak Associates added most to Pfizer in Q3 2024, an estimated $5.09M increase.
  • Oak Associates's biggest Q3 2024 reduction was KLA, cutting an estimated $15.7M.
  • Oak Associates fully exited Intel in Q3 2024, selling an estimated $5.53M.
  • Oak Associates's ten largest holdings make up 47% of its $1.49B portfolio in Q3 2024.
  • Oak Associates opened 2 new positions and closed 6 in Q3 2024.
  • Oak Associates's portfolio value fell 1.4% quarter-over-quarter to $1.49B.

Based on Oak Associates's 13F filing for Q3 2024, filed 12 Nov 2024.